Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

CEO

Mr. Walter V. Klemp

Employees

Country

United States

ISIN

US60855D4088

Listings

0 Comments

Share your thoughts

FAQ

What is Moleculin Biotech stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Moleculin Biotech stocks are traded under the ticker MOL0.MU.

When is the next Moleculin Biotech earnings date?▼

Moleculin Biotech is going to release the next earnings report on May 07, 2026.

What were Moleculin Biotech earnings last quarter?▼

MOL0.MU earnings for the last quarter are 2.25 EUR per share, whereas the estimation was -5.28 EUR resulting in a +142.69% surprise. The estimated earnings for the next quarter are N/A EUR per share.

How many employees does Moleculin Biotech have?▼

As of April 15, 2026, the company has 17 employees.

In which sector is Moleculin Biotech located?▼

Moleculin Biotech operates in the Other sector.

When did Moleculin Biotech complete a stock split?▼

Moleculin Biotech has not had any recent stock splits.

Where is Moleculin Biotech headquartered?▼

Moleculin Biotech is headquartered in Houston, United States.